Peristomal Pyoderma Gangrenosum Responding to Risankizumab.
Evidence to support available therapies for pyoderma gangrenosum (PG) is limited. Many patients do not respond to topical therapies such as tacrolimus or topical steroids. Currently favored oral systemic treatments (eg, cyclosporine and steroids) achieve complete remission in only 50% of patients an...
| Publicado en: | Advances in Skin & Wound Care Vol. 34; no. 6; pp. 327 - 330 |
|---|---|
| Autores principales: | , |
| Formato: | case study pictorial Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
Jun2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150384628&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 150384628 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15277941 38T jtl: Advances in Skin & Wound Care issn: 15277941 maglogo: N pubinfo: dt: Jun2021 vid: 34 iid: 6 pid: 5086 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 150384628 150384628 150384628 10.1097/01.ASW.0000744324.59877.df 150384628 ppf: 327 ppct: 3 formats: tig: atl: Peristomal Pyoderma Gangrenosum Responding to Risankizumab. aug: au: Weigelt, Maximillian A. Kirsner, Robert S. affil: In Miami, Florida, Maximillian A. Weigelt, MD, is Clinical Research Fellow, Dr Phillip Frost Department of Dermatology & Cutaneous Surgery University of Miami Miller School of Medicine sug: subj: Ostomy Adverse Effects Pyoderma Gangrenosum Drug Therapy Antibodies, Monoclonal Therapeutic Use Dermatologic Agents Therapeutic Use Treatment Outcomes Female Adult Interleukins Antagonists and Inhibitors Biological Therapy Patient Safety Surgical Wound Infection Drug Therapy Adult: 19-44 years Female ab: Evidence to support available therapies for pyoderma gangrenosum (PG) is limited. Many patients do not respond to topical therapies such as tacrolimus or topical steroids. Currently favored oral systemic treatments (eg, cyclosporine and steroids) achieve complete remission in only 50% of patients and have unfavorable adverse effect profiles. There is a growing body of evidence to support biologic agents for the treatment of PG, but their exact role remains unclear. Here the authors present a patient with peristomal PG, the first reported case of PG responding to treatment with risankizumab, an anti-interleukin 23 monoclonal antibody. Risankizumab may represent an effective and relatively safe treatment for PG that merits additional exploration in prospective, controlled studies. pubtype: Academic Journal doctype: case study pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|